In vitro diagnostics is defined as medical devices which are used by laboratories to perform diagnostic tests inside a laboratory. These tests are performed on samples collected from a patient’s body such as blood, urine, and tissues. Furthermore, medical devices used to perform in vitro diagnosis also require the use of various technologies to conduct the tests. For instance, blood collected from a patient is analyzed for hepatitis infection by using enzyme linked immunosorbent assay technique to analyze the blood. Furthermore, the testing procedure also requires use of various reagents and the use of software for smooth operations. In addition, in vitro diagnostics are used for detection of various medical conditions such as infectious diseases, diabetes, oncology/cancer, cardiology diseases, autoimmune diseases, nephrology, and HIV/AIDS. Moreover, these tests are performed in various medical facilities such as hospitals, standalone laboratories, and academic & medical schools.

The global in vitro diagnostics market size was valued at $67 billion in 2019, and is expected to reach $91 billion by 2027, registering a CAGR of 4.8% from 2019 to 2027.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/336

Factors such as rise in awareness about healthcare, surge in incidences of chronic and infectious disease, and cost-effective diagnostic solutions are boost the growth of the in vitro diagnostics market. Similarly, rise in use of automated instruments and point-of-care diagnostic solutions, surge in government expenditure on healthcare globally, and accurate and faster test results supplement the growth of the in vitro diagnostics market. However, stringent regulations & policies and unclear reimbursement rules hamper the market growth. Moreover, high growth rate exhibited by developing economies are expected to present lucrative opportunities for key players in the in vitro diagnostics market during the forecast period.

COVID-19 Impact on Global In Vitro Diagnostics Market

The COVI-19 outbreak in China has spread to every part of world. This has led to nationwide lockdowns in order to prevent the spread of infection. Thus, this in turn has led to suspension of various operations in every business. Similarly, the in vitro diagnostics industry is also hit by the outbreak. For instance, the key players of in vitro diagnostics market responded to outbreak through quick launch of new testing kits for COVID-19. Furthermore, some in vitro diagnostics services were affected in a negative manner due to the lockdowns. Thus, the overall impact on in vitro diagnostics market was low as the new demand for testing kits compensated for the losses due to fall in demand of other services and product.

The report segments the market across into product & service, technique, application, end user, and region. On the basis of product & service, the market is segmented into reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.

The clinical chemistry segment is also further divided basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others.

On the basis of product & service, the reagents segment acquired the major share of in vitro diagnostics market. The growth of this segment is attributed to the fact that reagents are a vital part of every in-vitro diagnostic test. Hence, the factors aforementioned contribute to the growth of this segment. In addition, the instruments segment is expected to grow at the fastest CAGR during the forecast period, owing to rise in focus of key players toward launching of new instruments. 

On the basis of technique, the molecular diagnostics segment is expected to exhibit the fastest growth rate during the forecast period. This growth is attributable to rise in prevalence of cancer, surge in adoption of personalized medicine, and increase in focus of key players toward developing more advanced molecular diagnostic systems.

By application, the market is segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. The infectious diseases market has the highest potential, owing to increase in incidences of HIV-AIDS, hepatitis, and other infectious diseases. 

On the basis of end-user, the standalone laboratory segment occupied a major share of the in vitro diagnostics market, owing to the fact that standalone laboratories employee highly skilled laboratory technicians who can perform complex in vitro diagnostic tests. Thus, these medical facilities receive a greater number of patient samples for in vitro diagnostic testing, which fuels the growth of the market. The point-of-care segment is expected to grow at a significant CAGR, owing to surge in adoption of novel and advanced in vitro diagnostic tests which can be used in home care setting for diagnosis of various chronic diseases such as diabetes.

North America is expected to be the leading regional market for IVD during the forecast period, owing to its well-penetrated healthcare system and higher healthcare awareness among patients, including Obama’s Affordable Care Act (ACA) act, change in technology, and rebounding American Economy. Furthermore, other factors such as easy availability of devices, rise in the awareness related to use of these products and presence of large number of geriatric populations suffering from various chronic diseases also contribute to the growth of the market. Moreover, presence of large number of key players in North America is another major factor that drives the growth of the market. In addition, Asia- Pacific is expected to register fastest growth rate during the forecast period, owing to surge in healthcare expenditure and rise in prevalence of diabetes in the region. Other factors such as huge patient base of other chronic diseases that require IVD testing also boost the growth of market in Asia-Pacific.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/336

Key Findings Of The Study:

• The reagents segment accounted for more than half of the share of the global in vitro diagnostics market in 2019.
• The instruments segment is expected to grow at the highest CAGR from 2020 to 2027.
• The infectious diseases segment accounted for around one-thirds share of the global in vitro diagnostics market in 2019.
• Europe accounted for around one-fifth share of the global market in 2019.
• Asia-Pacific is expected to provide lucrative growth opportunities from 2019 to 2027.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.